Elevated glucose levels emerging in roughly one-fourth of lung cancer patients receiving Clovis Oncology Inc.'s next-generation EGFR inhibitor CO-1686 may have overshadowed the promising interim progression-free survival (PFS) rate presented at the American Society of Clinical Oncology meeting over the weekend, at least on Wall Street, but analysts say the targeted covalent inhibitor remains a contender against Astrazeneca plc's AZD9291.